Does Ocugen Have a Real Shot at the U.S. COVID Vaccine Market?

·5-min read

Small biotech Ocugen (NASDAQ: OCGN) hopes to join the group. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether Ocugen has a real shot at becoming a winner in the U.S. COVID vaccine market. Keith Speights: It looks like Pfizer and BioNTech are very close to finalizing a deal with the European Union to supply up to 1.8 billion doses of their COVID-19 vaccine through 2023, so it's a multiyear deal.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting